<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Benefit of leukotriene inhibitors in asthma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Benefit of leukotriene inhibitors in asthma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Benefit of leukotriene inhibitors in asthma</div><div class="cntnt"><img src="data:png;base64,iVBORw0KGgoAAAANSUhEUgAAAccAAAEwCAMAAAD1tUohAAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAYFBMVEX///8iIiJfX1+qqqqIiIgHN///BQUAAADw7/IzMzMRERGZmZlwjP+7u7vd3d1ERET/dXUnUv93d3earv//m5xHbP+3xf/Z4f//u7vMzMz/Q0P/Jib/z8//3998PKbNFz9cEF0PAAATe0lEQVR42uydi5ajKBCGK2oCGhNjjJpLZ/f933LVdPf2RUCgCtCWndkzZ+aMk8pnFX8VBQCsYx3rWMc61rGOdSx5sAWPv2HgO8cFv6J/w8CV48px5bhyXDmScRRPnwvhuGQDv3IU/vFSOC7YwJXjQjlmLFsyx7SPqMVx8Rz3nZn7RXOMIWLnxXMsWMaKxXPcL53jkbEDY0dYeFy9LZ1j0jljypJl+2PMNkvnuBkyq82yOfIh4iyZ4xBT+9i6aI77xftjNGicgkVr3rHWAdY6wMpx5bhyxOF4zA4wCPdXGj1Hjut6R68QepEH5/Q2W39c5tBef+w5cnaDleP8OcasS6SjlePcOe6zI9yy+GssXjnOkOOhX7srkll8QyYcZyfmTOfHLIHbIHgWyXF+Yk6bY/SKoYdufkxgsf44OzGH1i+3QI5zEnMrx2WIuZXjMsTcynEZYm7luAwxt3JchpFyjjFfOS6AI2fxynHeHNNhrBxnzpG/50srx5n7Y8ySOI5XjrOfH9PDx/9WjmvesXL0yfGo+4i/so48M45pmtxWf1wAx76lPDkSmsi3ddWGwnF6tWNu8+M+yjqU0ZGMY1VX+bbMmxA4alQ7Zqhz9qlO9qhrYtkTbPKyc0vukaNutWN2HG9Jygg5ttuPX1T1tiSOsGKO2tWOmXEcIG6iG1BxzPMvX2ZDHGEl/qhb7Zidzsmig8W3pVY5PzywHSJs65yjbrVjbv64p5XkVTkSavsIm7eOOS4776A2sa7Gf78TPgQRVsTxuHiOUQRJAof0QGNiuxVrVIIIK+KoWe2YYb9cmvY/Yiq9+lXlAH2EFXLUr3asHH8lj/LRp5Z5w0k5GlQ7ZseRdz+oODbltOhbIUVYmc7RrHbMsL4qzI+HrUg8Yizbm5moCKtf85MhwjZkHLWrHQvi+NqKdExvcGZGJv5KHidEWKvinYijQbVjbnkHfw3BX3iXsYeNkYlVrfsJe+GzrfO8alpMjgbVjlnmHcK/8G78d4Ew2cSyMvmUbVPldYezHHhyFH/cW70Ss9GrCo7vyZfuVqTPErnZaJv8k2czjedf7gdQcyxiMxOnqxz5tNnzLD94GnE0qHbMMu+QzY/HNDE0cYtaq+EfPOueZ6tZz9HOkkPi2It5O73axdDD8Od7fROrksaobvr84PlTDi2RYw/xxxK8bv5oZ2JdkdrXDjy322kctasdLFSIJnmHjYmyEjntxDGWd2i/rSxUiOB43arKYeVIANE1x7IJh6NB1GGhQnTMsSkhHI7yakdgHBUQxRxJ5sc8D4ijLEu2XgxwDFHEMcko9CrftvPgaL0Y4BqiiGNGknfol8hpOUqqHZaLAa4hCjlGFHG1rILiKNOrlosBriGKOJ4pOPpIHi05Gi4GOIco4phSxFUvKscw77BbDLAfrfbOF3ccyzYsjtK/ZLUYYO+N+lPQeN5BUJfzkjyCxblkxosB9iOvAYEjJ+FYVzAff/RbB6gMlMRvjjGL9eLqJAngJ3lUcAyzLtduG/DBcZKJfpJHKUftaocjjmUOGBxp4qqPErmCYxbmekdeAg5HiqnDsr+KhmMUYlxttm3AHD0lj1KO5xA58m0DAXP0pXJkHNMQ42qdQ8AcqxJWjtMmR47JMUmjfYp4fo6v5FGed4TXD9Aax61RjhFjKWQJmomeSuRSjjxAjtx8SWi0X45FUQrpGc1EfypHyNEkSybnWNeAyzE+p7DB4+gteZwXx8oibI2vd2yKTcHQznlo/KmcOcXVdtsALsfbsHMeTa/6DKszqpOXOSBzhGNy3qOZyP0lj3PimJeAzpEDl8wbvOj07HGyid5K5LPi2Ni97aMci+KYMfEWyE7MQhpNNrGsVo60k6NQryYJS5kwskZRX5ycaqK/ErmKo261g5JjnQMBxzhiB3H+yNMsKvhUE72qHBlHrWoHcb+ccT1OGle7tINxMcekgGST/G+e3ESvKkfWL6dd7aDj2Fh/SeP9q/15XeK42u9+2G8mmug1eZRz1K12kHHk9hJCUCdPeHwWenpa9FJoool1FShH/WoHGce6BhKOPDl3Q6gAbun0vMNniVzBUbvaQcWxKjkNxwivz8pv8ijXq7rVDiKOtimHmGPWhZxzhnL0ms8SuYpjGPVVXuZAw7FTAEUEKYY/+lY56n6ATeKZY14DGcf9Oev+Q+DoOXmcwJExv/cFNDh52fi6VXTDmR+55+RRyrE4c55ke3b2yRFlcgRxn1V8jsGeo3eVI68DdGkw88yxzIGQI1afle/kUeqPGxadNyz2yjEvgZAjVp+V9+RRynHfT47Fwed9Og3avEPaZ+Vf5UjzjtvZc/7ItxWQckTqs/KePELY++bqGig5YvVZ+U8eIeh9cxj1OClHpD6rAFROyPvmWsykjLDPKoDkEcz3zWk2IRlMjmUOxBwPB5tvK6DkEcz3zWk2IRmkHDVQcyxSrUcI+gFCUDnm+630mpBMUg5OzjFOEfaVe+6vsuWo14RkMDk2QM4R5ZyHEJJHMF+30mtC0h5lDjPhGITKkd5XLu160GpC0p8cS3DA8RhzfrOsk1clBM5R3vWg1YSkPzm2LjimGw4x21txDCJ5lOcd0q4HnSYk7ZRjW4EDjrxfAuDMqi4XQolczlG/6wGNY52DG46d3r7ZcQxE5Ug56nY9YHHErMfJ88dhZc6qvhpG8ijPO3S7HjA48v5m0hbccLSvrzaBqBzFfiu9rgeGwbDEusB7Akf7+mowYTWUdStKhmKOtvd38ECSRwhi3YqaoZCj9f0dYZTIVXmHi3UrFwyFHNUWFhupiWU1B47U5wS6YijmqLLwnEk5BlIil3LknPS8R5cMhRxVFiabRMoxHJUjOQeJ7t5A1wyFHBV18kN23Es5hqNynHP0wdCQY38b2wfH0SWdcJJHaVy96a4GTLo0yANDcd4hXZl7XWzBxFc/1dUMOBqsBoR7aZDxOfOyuBpMiVzOUX81gE1wxzYYjpNOQpRxDCh5BNU+nRsuR9/HsKPe3xFMiVwRV7VXA1i47khwf0cbkspxe86Dx3wL/5z5kJJHcHrOg0d3xOfIQ0oeAe2cwCn9cv6P70bkWIUVVh2e9+hVp6NzDCp5dMoRxx3frqfT/bG7YHCM+v7bwqhfLqzk0SVHW8vfAT7up9P17aILcrTPKj13ctVsP3JgKkfav6r7tso5GjfBfQP48Zu6IEc4nt9LpkbnA4SVPErrANpvq/xShMEdn7vd7t6NUz+u3XjqAjQEKeZYmCzNNYGpHDFHg7eVqd3xfoJnj2/g2APd7UbISgGagRyNq1GiWQb4fEBezYyjztvKlO54eYw97hdZOUAjkLh9VqElj9K4qv22MpU78t0V86PrgMTtswqrRK7Uq3h9HS93PN1xP7sGSMM+K4GJZTUjjph9j4M7vu2e4AukWZ/V90d8lqxC6q9Sc0Tse3y54+OE/ukngzTqsxI9JrjkERz1PQ7ueHkQfPypIFH3I4enctzccz24I7LI0QSJybEqYU4c8e5/HNwRW+TogTTosxI+pq7+JsfBHa87qsLyJJCI568GVyJX5R1Y58wP7vi4kJkwBSTi+ashqhyre8oUm1i+uePpQWjDBJCI568GVyJXcFS9rYpNLP+7Y9XXx6/gFSTe+atNiCrH4p4y1SaWT3fs7b6faK1QgsQ7fzXMsGp8T5lyE8tXd6QTOVNBop0PwENMHsH4njLlJpav7sgJRc5EkOPnWSXJea95nlWAJXIFR+nbqtzE8jH6kjJV6qgBEu08q7KaG0dl/+qUuNrXPp67N/ANEus8qzCTRynHY8y7n5Yc+9eXWuRMAWl0nlXBWPHjMYGonLdr3zAxdX603zfXu+P14eoVloA0Oc8q2XD+45o25l3lvAg+7qfLdapeRdg317kjp00dJ4I00at9w2Dy48hnj8nj83o6PXa7XwTV+aP1vrneHZ2IHCVIk/OsNt2f7b8fYc4qXwTvL4Jcf35E2DfXuSN+E4ARSJP7Ar5w/EytLm4J8utFSdAq75jEsXdHVyJHAdLkvoA+rv48Sv9x544Jnq5P3S//u5mHve2+uc4dLw/XQWgcpMl9AWM6h98f5EnUi+BjKkFlXE01/3322x1dihwpSKN+gJG8Q39Hgi7BQYxetV8WMUft2y3Yb3d0KnJkIBH7Ot6oYuvJjKAyf7TsB+jc8epW5EhAYvZ18BNFlHl7WEVsOo6dOz4uAGGAxL1X97I74Tuj3SPJ+jo6d3QvcoQgke/VxY6tls4IVn0dco5l8/QgckQgse/VRY2t3cOsA5d5X4ecY1U7Tx1lIPHv1cWLrdfH3V5GGPd1KDiWDX0TgALkU6lXre7VRYqtGM4I5n0dikd17uhL5HyMp3J+tLz3ASW2ojgjGPd1KB7Ft42X1FHx2bDvfbCOrUjOCFT11bx21ARgw/F2TrjFt/UeW58BOCMQnUvWuaNXkTOJY3/kc3a049jnfVf/zghE55LltWeRM4Vj1Ak5vdlx9Bu6msZWRGeUcdSPOuyLOz6uEDrHNH39tOQIz8fjaeSMV3wDf//aIOr8f9hTHZbIEXHkvP9py9Eotl53yMV2EUeDqMM+3fHgpz6uyVHzRgTJkZa6sZXf0UtdIo4GUefzkKA6MJGDw1GmIPRiK7ozSjlqR53PQ4IuDz4Djq91AKwjgqbHVgJnlHE0voclr3dXmANHy2/LMLZSOCMFR74NTuQ44QjPKa07NM4oyzv0o8774TL/BCdy3HDsY+tF6YwnDm45Gj6KbwmOO5oJRxWmzmOvtAbiccz/ecCf5QjStsgLmTPic+TbAEWOO46S2ErpjPgc839DjKoOOYpiK6kzonPk/+z4H+c4GluJnRGdY+67CSAAjiOxldoZsTm2YYoc1xx/xFZ6Z8TmmIfVBOCN47fY6sAZbTiObGJpAxU5FhwP3zfWT3/AR9+lfYcxLcexTWWhihxzjscsM+T43hZ52p1cGqjPcWzz/L8XWBbH7k3dmHLsY+vFkTNacBzbPP8vLIzjf+2dXZejIAyGAdkN4BHO8c7//0c3Absd22nV1o9q31y1M1YSHhKjAkmtep3jKst51uRIHyqvcyy7dTVtUj3Hoxj4Wly9XTy/UMJHK5zmJX9MubfM6xn9hocvmeecjeMl7pyZ4++L58HxcBxXY/RZHHcDA47gCI7gCI7gCI6fxPGThb7DQHAER3AER3AER3BchWMTKIxu7hFHD3GGKIxsS8CH0Pj+TINX+YtwnGTiLEuGclv47bnYwYPRxTgGq2xQowDG+iH6TrUjivAhNbnRIROW5jjFxHmWDOSu8Nvzo/n0K/hjJz+mbtT9p4znZtweO7bE9uZV/hIcJ5o405KrSXeF357ad6PIUhxzURZdLcLRjO1LUNNod968yl+C40QTZ1nyM2jfFX57JhXpwavRD+RoJwz5OjyPq9dX+XtytNOd92fht0nKhKi6UK0SV90icTVN6qmRE92+yl8qrro5cTXNYP5b4bfn7isN2H3ynAkcox/NRJsUuanxKZZ67zzHvuLwU6+PrEz3ozc3ve8wj7cuGY7Lp+l6ZGfTE+Kz3ve+Y4Ilb3DkFGpw84XnAHgOAI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7gCI7geAyOnuzJOS5p4b4co8wsshRkYpQ9JcetLNzZHz3VMretUeFuBtZJ/HEjC3fmaMmwgWQbGbG1JkpRdTKPqhIrnaZK1jFQOC7HjSzcmWNDuqFESazlD2xSclq7ju1iKyUUWfKH9seNLNw7zwlkqNEhcfTJsyIp1GVGbucpyIIi/urb7rgcN7Jwb46JQsj2RdXXKaxJ91ePUoHSmjnzrD+P4zYW7s0xr+LjEall6UnoVGVc4FgTk/PUtiXixENz3MbCvTl2Mis6lqUYtc8LVCUL4O+SzWmyLX/RtToux20sxPMcPM8BR3AER3AER3AER3AER3AER3AER3AER3AER3AER3AER3AER3AER3AER3B8yPHE8h0GQiAQCAQCgUBeyIghp8gskRGfoz/AERzBEXqjP6A3+mMTvZtH5VzeX5j1hvzaeLxbEPfNHNMV3KNiJbnD9uEo6/t9BMdRieTbT+aYeKQZcJzQUZXsZ1FLXaJczYuiMbJCNLpElFxxWaJGp1yktPNELRPvyKRcmyhSkvWj2kqZxVU48vDSeYMVqYTUin8W1XgI5vpF7LO6+3aO3qpQ5auiteKPzJEZqtbkimulHljxR+m4yoVG6vDVoWxPUwf+p1UVRf60hssyR+cv/shtWB2VaYpqfcuie6uPz/HPfLmeoSOn2P9susRVYeatY7bX8oD/46qu+wphOQJbWcl9+Sf/ovq9UN3f+TK8PnJQ4MZLa6WcX1Gtb1l072sOfq8/tnm3EjfkWGv5RNXd9VE4usuRHbtD03Nk7DYlq1aJqzlf7VvrOVb/1QoVOF4SesEjcVUcSjrHBQmbyTv+mxzkJKUtHF0wyplGOFZBdjvhH3S5hOsCO38849i31sfVrFrfsuhuThBX37pbzKGwla2gOM9xPuc5UkzSlVqQvtyTSDH0wlE1Xrb/ynFVkg3h2JduTEatyLFvTVTxsah2aRl5zhJyyf4jNeiPE3A0Cf3xbXqjP8ARHMEReqM/oDf6Y1RvCFZiQCAQCAQCgbwp/wBQ6UAyrtNE+QAAAABJRU5ErkJggg=="/></div><div class="graphic_lgnd">Effect of the leukotriene synthesis inhibitor zileuton (A) and the LTD4 receptor antagonist zafirlukast (B) on FEV<sub>1</sub> in patients with mild to moderate asthma. Both drugs significantly improved the FEV<sub>1</sub> comparedÂ with placebo.</div><div class="graphic_reference">Data from: 

<ol>
<li>Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059.</li>
<li>Spector SL, Smith LJ, Glass M, et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618.</li></ol></div><div id="graphicVersion">Graphic 54679 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
